EconomyLilly to buy Calytrix Bio for up to $1.5 billion
Privately held biotech Calytrix Bio said on Monday that Eli Lilly has agreed to acquire it for up to $1.5 billion in cash, expanding development of treatments for rare blood cancers.
Lilly to buy Calytrix Bio for up to $1.5 billion
